Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

 

ID#NCT03972280

Recruitment Status:  recruiting as of August 2020.

 

Estimated Completion Date: July 2021

 

Sponsors and Collaborators: CSL Behring

Information provided by (Responsible Party): CSL Behring

Brief Summary: Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. CSL324 is a novel, recombinant therapy that may treat diseases caused by increased numbers of neutrophils at sites of inflammation.

Please link complete details https://clinicaltrials.gov/ct2/show/NCT03972280

Locations: Australia

Contact:  Trial Register Coordinator, 610-878-4000, clinicaltrials@cslbehring.com

SUBSCRIBE HERE!

© 2021 by HS Connect, LLC  |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579